Expression of TGFβ1、TIMP1 in liver cirrhosis and pathological significance

Jiang Ying; A YiTuLa

Issue 1

Jan. 2009

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2009 > 25(1): 39-41

PDF( 206 KB)

转化生长因子-1和基质金属蛋白酶抑制因子-1在肝硬化组织中的表达及其临床意义

Published Date: 2009-01-20

Abstract

Abstract

Objective To detect the expression of transforming growth factor beta 1 (TGFβ1) , tissue inhibitors of tissue inhibitors of metalloproteinase-1 (TIMP1) in liver cirrhosis tissues.Methods All 57 liver cirrhosis specimens were detected by immunohistochemistry (S-P) .Results Proteins of TGFβ1 and TIMP1 were detected in all liver tissues from 57 liver cirrhosis patients, all in cytoplasm but not nucleus.Conclusion TGFβ1 and TIMP1 may play an important role in the development of liver cirrhosis, especially they were tightly correlated with clinical pathologic factors.
- liver cirrhosis,
- Transforming growth factor-β1 (TGFβ1) ,
- tissue inhibitors of metalloproteinase-1 (TIMP1) ,
- extracellular matrix,
- immunohistochemistry

FullText(HTML)

References(6)

References

[1]阴赫宏, 马红, 贾继东, 等.重视肝纤维化细胞外基质降解中TIMPs的研究[J].临床肝胆病杂志, 2002, 18∶259-261.

[2]廖丹, 江建宁, 罗光汉, 等.TGFβ1和smad4mRNA在慢性病毒性肝炎、肝硬化组织中的表达及意义[J].临床肝胆病杂志, 2005, 21∶89-91.

[3]张愚, 屈文东, 黄华.bFGF及TGFβ1在实验性肝硬化中的免疫组化研究[J].胃肠病学和肝病学杂志, 2005, 14 (1) ∶40-44.

[4]叶伟东, 陈永平, 徐少杰, 等.肝纤维化大鼠肝脏Bcl-2、Bax、增殖细胞核抗原的表达及重组转化生长因子β1疫苗对其表达的影响[J].中华传染病杂志, 2007, 25 (7) ∶398-402.

[5]郭海峰, 刘洋, 徐华锋, 等.肝纤维化基质金属蛋白酶-26/基质金属蛋白酶组织抑制因子-1 mRNA的表达[J].中华肝脏病杂志, 2006, 14 (2) ∶134-136.

[6]段志军, 胡祥.免疫性肝纤维化中肝组织中基质金属酶-1及其抑制因子-1的表达[J].中华消化杂志, 2002, 22∶566-567.

Relative Articles

[1]	Chinese Association of Integrative Medicine, Chinese Association of Integrative Medicine, Chinese Medical Association. Guidelines for integrated traditional Chinese and Western medicine diagnosis and treatment of liver cirrhosis[J]. Journal of Clinical Hepatology, 2023, 39(11): 2543-2549. doi: 10.3969/j.issn.1001-5256.2023.11.005
[2]	Xianbo WANG, Ke SHI. Integrated traditional Chinese and Western medicine diagnosis and treatment of hepatic encephalopathy: Advances and perspectives[J]. Journal of Clinical Hepatology, 2022, 38(9): 1969-1973. doi: 10.3969/j.issn.1001-5256.2022.09.004
[3]	Jiaqi LIANG, Wen LIU. Integrated traditional Chinese and Western medicine diagnosis and treatment of hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2022, 38(9): 1974-1979. doi: 10.3969/j.issn.1001-5256.2022.09.005
[4]	Shili JIANG, Ping LIU. Research advances in integrated traditional Chinese and Western medicine therapy for liver cirrhosis[J]. Journal of Clinical Hepatology, 2022, 38(9): 1953-1955. doi: 10.3969/j.issn.1001-5256.2022.09.001
[5]	Changqing ZHAO. Integrated traditional Chinese and Western medicine diagnosis and treatment of liver cirrhosis with diabetes[J]. Journal of Clinical Hepatology, 2022, 38(9): 1980-1985. doi: 10.3969/j.issn.1001-5256.2022.09.006
[6]	Lei WANG. Integrated traditional Chinese and Western medicine diagnosis and treatment of cirrhotic ascites[J]. Journal of Clinical Hepatology, 2022, 38(9): 1956-1961. doi: 10.3969/j.issn.1001-5256.2022.09.002
[7]	Chinese Association of Integrative Medicine. Expert consensus on the diagnosis and treatment of acute-on-chronic liver failure with integrated traditional Chinese and Western medicine[J]. Journal of Clinical Hepatology, 2021, 37(9): 2045-2053. doi: 10.3969/j.issn.1001-5256.2021.09.009
[8]	Wang XianBo, Zhang Qun, Gao FangYuan. Prediction of acute-on-chronic liver failure and integrated traditional Chinese and Western medicine therapy[J]. Journal of Clinical Hepatology, 2020, 36(1): 19-25. doi: 10.3969/j.issn.1001-5256.2020.01.003
[9]	Jiang ShiLi, Liu Ping. Current status and perspectives of integrated traditional Chinese and Western medicine therapy for hepatobiliary and pancreatic diseases[J]. Journal of Clinical Hepatology, 2020, 36(1): 10-13. doi: 10.3969/j.issn.1001-5256.2020.01.001
[10]	Xu Meng, Sun FengXia, Li Jie, Li XiaoLing. Research advances in the role of intestinal flora regulation in the traditional Chinese and Western medicine therapy for nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(6): 1378-1381. doi: 10.3969/j.issn.1001-5256.2020.06.041
[11]	SHANG Dong, ZHANG GuiXin, ZHANG QingKai. Application of minimally invasive integrated traditional Chinese and Western medicine therapy based on the SELECT concept in the diagnosis and treatment of hepatobiliary and pancreatic diseases[J]. Journal of Clinical Hepatology, 2020, 36(12): 2641-2645. doi: 10.3969/j.issn.1001-5256.2020.12.002
[12]	Liver Disease Committee, Chinese Association of Integrative Medicine. Guidelines for the diagnosis and treatment of liver fibrosis in integrative medicine practice (2019)[J]. Journal of Clinical Hepatology, 2019, 35(7): 1444-1449. doi: 10.3969/j.issn.1001-5256.2019.07.007
[13]	Liu Ping. A clinical analysis of strengthening integrated traditional Chinese and Western medicine therapy for prevention and treatment of liver cancer[J]. Journal of Clinical Hepatology, 2016, 32(4): 615-618. doi: 10.3969/j.issn.1001-5256.2016.04.001
[14]	Li Jun. Clinical research progress in integrated traditional Chinese and Western medicine therapy for HBV-related liver failure[J]. Journal of Clinical Hepatology, 2015, 31(1): 42-47. doi: 10.3969/j.issn.1001-5256.2015.01.010
[15]	Wang XianBo, Sun Le. Progress and prospect of diagnosis and treatment of hepatic fibrosis by integrated traditional Chinese and Western medicine therapy[J]. Journal of Clinical Hepatology, 2015, 31(1): 38-41. doi: 10.3969/j.issn.1001-5256.2015.01.009
[16]	Wei BeiHai, Zhou Tao. Current and future perspectives on integrative traditional Chinese and Western medical management of gastroenterological diseases[J]. Journal of Clinical Hepatology, 2013, 29(4): 241-244.
[17]	Yao XiXian, Yao DongMei. Combination treatment of Chinese traditional and Western medicine in chronic hepatitis and liver fibrosis[J]. Journal of Clinical Hepatology, 2013, 29(4): 245-248+252.
[18]	Liu ChengHai, Xing Feng. The potential benefit managing ascites due to cirrhosis using an integrative medicine approach[J]. Journal of Clinical Hepatology, 2013, 29(4): 253-256.
[19]	Liu JianJun, Li Nan, Zhi Hong, Wu XiaoYing. Current clinical perspectives and implications of cirrhotic ascites in China[J]. Journal of Clinical Hepatology, 2012, 28(9): 701-703.
[20]	Tang ZhaoYou. Combination of traditional Chinese medicine and western medicine in the treatment of liver cancer[J]. Journal of Clinical Hepatology, 2011, 27(5): 449-450.

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (2633) PDF downloads(746)

转化生长因子-1和基质金属蛋白酶抑制因子-1在肝硬化组织中的表达及其临床意义

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

转化生长因子-1和基质金属蛋白酶抑制因子-1在肝硬化组织中的表达及其临床意义

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content